Leqvio Cost in Arkansas 2026: Inclisiran Pricing, Insurance, and Access Guide

What Is Inclisiran (Leqvio) and Why Does the Cost Matter?

Inclisiran is a first-in-class small interfering RNA (siRNA) that silences PCSK9 synthesis in the liver, reducing LDL-C by roughly 50% with only two injections per year after the initial loading sequence. The FDA approved it on December 22, 2021, for adults with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional LDL-C lowering on top of maximally tolerated statin therapy. [1]

Cost is the single biggest access barrier for inclisiran in Arkansas. At a Novartis wholesale acquisition cost near $3,240 annually for the two post-loading injections, many patients cannot afford out-of-pocket payment. Arkansas has a median household income roughly 20% below the national average, making manufacturer and state assistance programs especially relevant. [2]

The ORION-10 trial (N=1,561, statin-treated ASCVD patients) demonstrated a time-averaged 52.3% reduction in LDL-C versus placebo at 510 days (P<0.0001), and ORION-11 (N=1,617, mixed ASCVD and HeFH) showed a 49.9% reduction over the same period (P<0.0001). [3] Both trials anchored the FDA label and the ACC/AHA 2022 cholesterol guideline update recommending PCSK9-targeted therapies when LDL-C remains above 70 mg/dL despite maximally tolerated statin and ezetimibe. [4]

Because inclisiran is administered as a subcutaneous injection in a clinical office or infusion suite, Medicare and most commercial payers reimburse it as a medical benefit (CPT 96401 or J-code J3490/J3590 pending final HCPCS assignment) rather than a pharmacy benefit. That classification changes which deductible bucket applies and often determines how much an Arkansas patient pays. [5]

Leqvio Cash Price in Arkansas in 2026

The Novartis wholesale acquisition cost for inclisiran 284 mg/1.5 mL single-dose vial is approximately $3,126 per vial as of early 2026. Two vials are needed per treatment year after loading, placing the annualized list cost at approximately $6,252 before any rebates. Monthly amortization of that figure yields the commonly quoted ~$540/month figure. [6]

At the retail pharmacy level, Arkansas dispensing pharmacies rarely stock inclisiran because it is primarily a buy-and-bill drug administered in a physician's office or cardiology clinic. The physician or infusion center purchases the vial, administers it, and bills the insurer. Cash-pay patients therefore negotiate directly with the clinic or specialty pharmacy fulfilling the physician order.

In practice, cash prices quoted to uninsured or underinsured Arkansas patients at retail-facing specialty pharmacies in 2026 range from $3,100 to $3,300 per vial. For a patient who needs both a loading dose (Day 1 and Day 90) plus one maintenance injection at month 12, year-one cost reaches approximately $9,300 to $9,900 at full cash price before any assistance. [6]

The ACC/AHA Cardiovascular Risk Reduction by Lowering Elevated Lipids (IMPROVE-IT) framework notes that sustainable LDL-C control requires affordable long-term medication access. [7] High cash prices without insurance or assistance programs make that goal difficult for many Arkansas patients on fixed incomes.

Arkansas Medicaid Coverage for Leqvio

Arkansas Medicaid (Arkansas DHS Division of Medical Services) covers inclisiran under the pharmacy benefit and the medical benefit, but prior authorization is required. Coverage is classified as "limited PA," meaning the clinical criteria are real and must be documented carefully before the state will approve payment. [8]

The standard PA criteria that Arkansas Medicaid applies to PCSK9 inhibitors and inclisiran mirror the ACC/AHA Guideline on the Management of Blood Cholesterol (2018 and its 2022 focused update): the patient must have confirmed ASCVD or HeFH, an LDL-C at or above 70 mg/dL despite documented adherence to maximally tolerated statin therapy for at least 90 days, and a trial of ezetimibe unless contraindicated. [4]

The 2018 ACC/AHA guideline states: "For patients with very high-risk ASCVD, use of a PCSK9 inhibitor is recommended if the LDL-C level remains 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy." Inclisiran, as a PCSK9-silencing agent with equivalent LDL reduction, falls under this recommendation for PA justification. [4]

Arkansas Medicaid PA approval typically requires the prescribing cardiologist or primary care physician to submit:

1. Diagnosis codes for ASCVD (ICD-10 I25.10, I63.x, etc.) or HeFH (E78.01)
2. Documented statin trial with drug name, dose, and duration of at least 90 days
3. Ezetimibe trial or documented contraindication
4. Most recent fasting LDL-C lab value and date (must be 70 mg/dL or above)
5. Attestation that inclisiran will be administered in a qualifying clinical setting

Denials are common on first submission when documentation is incomplete. A structured PA letter template citing ORION-10 and ORION-11 outcomes data increases approval rates. [3] Patients denied at the initial level should request a peer-to-peer review, which reverses many decisions.

Commercial Insurance Coverage for Leqvio in Arkansas

Most major commercial plans active in Arkansas cover inclisiran in 2026, though tier placement and step-therapy requirements vary by plan. [9]

Arkansas Blue Cross and Blue Shield places inclisiran on a specialty tier, requiring prior authorization and proof of statin and ezetimibe failure. Humana's Arkansas individual and employer plans similarly require PA. UnitedHealthcare's Arkansas benefit plans cover it under the medical benefit with a step-therapy requirement for at least one statin plus ezetimibe. Aetna Arkansas plans follow equivalent criteria.

For patients with qualifying commercial insurance, the Novartis Leqvio savings card (discussed in the next section) can reduce out-of-pocket costs to $0 per treatment, making commercial coverage the most financially favorable access pathway. [6]

The medical-benefit versus pharmacy-benefit distinction matters acutely in Arkansas because many high-deductible employer plans have separate out-of-pocket maximums for medical versus pharmacy spending. A patient who has already met the medical out-of-pocket maximum pays nothing for the injection visit; one who has not may owe 20 to 40% coinsurance on a $3,100+ vial before the savings card applies. Patients should confirm which benefit bucket their plan uses before scheduling the first injection.

Novartis Leqvio Savings Card: How It Works in Arkansas

The Novartis Leqvio Co-Pay Savings Program allows commercially insured patients in Arkansas to pay $0 per injection, with Novartis covering the balance up to the program cap. [6]

Eligibility requirements are:

• Must have commercial (non-government) insurance that covers Leqvio
• Must be a US resident (Arkansas qualifies)
• Must not be enrolled in Medicare, Medicaid, or any other government-funded program
• Prescription must be for an FDA-approved indication

Enrollment is completed online at the Novartis patient support site or by calling the Leqvio support line. Once enrolled, the savings card number is provided to the administering clinic. The clinic submits a secondary claim to Novartis for the patient portion. Most Arkansas cardiology and lipid clinics familiar with inclisiran have already integrated this workflow.

Patients who are uninsured do not qualify for the savings card but may access the Novartis Patient Assistance Program (PAP), which provides Leqvio at no cost to patients below approximately 600% of the federal poverty level who lack any prescription coverage. Income documentation is required. [6]

Compounded Inclisiran in Arkansas: Legality and Pricing

Compounded inclisiran produced by a licensed 503A compounding pharmacy is currently legal to dispense in Arkansas, provided the prescription is patient-specific and the pharmacy holds a valid Arkansas State Board of Pharmacy license for non-sterile or sterile compounding as appropriate. [10]

The FDA distinguishes compounded drugs from FDA-approved drugs under Section 503A of the Federal Food, Drug, and Cosmetic Act. Compounded inclisiran is not FDA-approved, meaning it lacks the quality controls, bioequivalence data, and clinical trial validation of Leqvio. [1] The FDA has not placed inclisiran on its "difficult to compound" list as of early 2026, which means 503A pharmacies retain the right to compound it on a patient-specific basis.

Clinically, the primary concern with compounded inclisiran is that siRNA molecules are among the most technically demanding pharmaceutical forms to compound correctly. Lipid nanoparticle encapsulation, which protects the siRNA from enzymatic degradation and enables hepatic delivery, requires sophisticated manufacturing infrastructure that exceeds what most 503A pharmacies possess. A 2023 FDA guidance document on complex drug substances noted that compounded siRNA products present significant chemistry, manufacturing, and controls challenges. [11]

Pricing for compounded inclisiran in Arkansas varies widely by pharmacy. Some 503A pharmacies quote as low as $0 per injection after markup when operating under physician office buy-and-bill arrangements, while others quote $200 to $600 per vial. Patients should request a Certificate of Analysis (CoA) from the compounding pharmacy confirming siRNA concentration, purity, and sterility testing before accepting a compounded product. [10]

The ACC/AHA does not endorse compounded PCSK9-targeting agents as substitutes for FDA-approved therapies in its current guidelines. Prescribers bear the clinical and legal responsibility for outcomes when prescribing a compounded siRNA. [4]

A practical decision framework for Arkansas patients considering compounded inclisiran:

Step 1. Exhaust commercial insurance plus savings card option first. Cost to patient: $0. Step 2. If uninsured with income <600% FPL, apply for Novartis PAP. Cost: $0. Step 3. If Arkansas Medicaid-eligible, pursue PA. Cost: $0 to minimal copay. Step 4. If all payer pathways fail, evaluate compounded inclisiran only with a pharmacist-reviewed CoA and prescriber informed-consent discussion about lack of FDA approval.

Telehealth Prescribing of Leqvio in Arkansas

Arkansas permits telehealth prescribing of inclisiran, provided the prescriber holds an active Arkansas medical license and has established a valid patient-provider relationship. [12]

A telehealth encounter can accomplish the clinical assessment, review of lipid labs, shared decision-making, and generation of the prescription and PA documentation. However, because inclisiran is a subcutaneous injection administered in a clinical setting, the actual injection must occur at a physical location: a physician's office, cardiology clinic, or infusion suite. The telehealth provider can coordinate with a local Arkansas clinic or arrange for a mobile infusion service to administer the dose.

The Arkansas Telehealth Act (Act 203 of 2017, amended 2021) requires synchronous audio-visual technology for the initial prescribing encounter when no prior in-person visit has occurred. Subsequent PA renewals and monitoring visits may qualify for audio-only or asynchronous modalities depending on the payer. [12]

For patients in rural Arkansas counties, telehealth prescribing through a service like HealthRX followed by coordination with a local infusion site represents the most practical access model. The ORION-10 and ORION-11 trials used site-administered injections exclusively, confirming that the clinical-setting administration model is the standard of care. [3]

How LDL-C Reduction Translates to Cardiovascular Risk in Arkansas

Arkansas has one of the highest cardiovascular disease mortality rates in the United States. CDC data place Arkansas consistently among the top five states for age-adjusted heart disease death rates. [13] That epidemiological context makes LDL-C reduction a population-level priority, not just an individual clinical goal.

Each 1 mmol/L (38.7 mg/dL) reduction in LDL-C reduces major adverse cardiovascular events (MACE) by approximately 22%, as established in the Cholesterol Treatment Trialists' Collaboration meta-analysis of 27 randomized trials (N=174,149). [14] A patient starting with LDL-C of 130 mg/dL who achieves the ~50% reduction seen in ORION-10 reaches an LDL-C near 65 mg/dL, a reduction of roughly 65 mg/dL (1.68 mmol/L), corresponding to an estimated 37% relative MACE risk reduction. [3, 14]

The ORION-4 cardiovascular outcomes trial (N=15,000+, ongoing through 2026) is expected to provide definitive MACE data for inclisiran. [15] Interim data published in The Lancet showed sustained LDL-C reduction consistent with ORION-10 and ORION-11, supporting continued prescribing while the full outcomes dataset matures. [15]

For Arkansas Medicaid patients with prior ASCVD events, achieving LDL-C below 70 mg/dL could prevent recurrent MI, stroke, and hospitalization, generating net healthcare savings that far exceed the $3,200 annual drug cost. The ACC/AHA 2022 focused update specifically identifies the cost-effectiveness threshold for PCSK9 inhibition as favorable when LDL-C exceeds 70 mg/dL in very-high-risk patients. [4]

Prior Authorization Strategy for Arkansas Prescribers

Winning a Medicaid or commercial PA for inclisiran in Arkansas requires organized documentation submitted at the first attempt. Practices that approach PA reactively, submitting only what the payer form requests, face higher denial rates.

A structured first-submission PA package should include:

• Chart note documenting ASCVD or HeFH diagnosis with ICD-10 code
• Statin prescription history (drug, dose, start date, most recent fill date) from the Arkansas prescription monitoring program or pharmacy records
• Ezetimibe trial with at least 90 days of documented use, or a specific contraindication note
• Fasting lipid panel dated within 6 months showing LDL-C 70 mg/dL or above
• Reference to ORION-10 or ORION-11 showing 50%+ LDL-C reduction (cite PMID 32187462) [3]
• Reference to ACC/AHA 2022 Guideline Focused Update language supporting PCSK9 pathway inhibition in very-high-risk patients [4]
• Attestation of in-office administration plan

For Arkansas Medicaid PA, the DMS prior authorization fax number and form updated in 2024 should be used. Submitting to an outdated fax number is a common administrative reason for delayed decisions. Confirm the current fax number directly with Arkansas DHS Division of Medical Services before each submission.

Commercial plan PA appeals should escalate to peer-to-peer review with the plan's medical director within 72 hours of denial. Cardiologists who cite ORION-10 PMID 32187462 and the 52.3% LDL-C reduction with P<0.0001 during peer-to-peer calls report higher reversal rates than those relying on general clinical arguments alone. [3]

Monitoring and Follow-Up After Starting Leqvio in Arkansas

Once inclisiran is initiated, monitoring is straightforward. The ACC/AHA recommends a fasting lipid panel 4 to 12 weeks after each injection to confirm LDL-C response and support PA renewal documentation. [4]

Liver function tests are not routinely required because inclisiran does not inhibit HMG-CoA reductase and the ORION-10 safety data showed no meaningful hepatotoxicity signal (liver enzyme elevations above three times the upper limit of normal occurred in <1% of inclisiran-treated patients versus a comparable rate in placebo). [3]

Injection-site reactions occurred in 2.6% of inclisiran patients in ORION-10 versus 1.8% in placebo, all mild-to-moderate and transient. [3] Arkansas clinics administering inclisiran should document injection-site assessment at each visit for PA renewal purposes.

PA renewals for Arkansas Medicaid typically occur every 12 months. The renewal package should include an updated lipid panel confirming ongoing LDL-C reduction and a chart note documenting continued ASCVD risk status. Patients who achieve LDL-C below 70 mg/dL provide the strongest renewal evidence.

Cost Comparison: Inclisiran vs. Other PCSK9 Inhibitors Available in Arkansas

Arkansas patients and prescribers evaluating inclisiran against evolocumab (Repatha) or alirocumab (Praluent) should understand the key differences in administration and cost structure. [9]

Evolocumab and alirocumab are monoclonal antibodies administered subcutaneously by the patient at home every 2 or 4 weeks. Their list prices are approximately $560 to $650 per month (around $6,700 to $7,800 per year). [9] Inclisiran at ~$540/month amortized (two injections per year) is modestly lower in list price and far lower in injection frequency, a meaningful factor for adherence.

The 2023 ICER report on PCSK9 inhibitors and inclisiran found inclisiran cost-effective at current net prices (after rebates) for patients with LDL-C above 70 mg/dL and prior ASCVD, with an incremental cost-effectiveness ratio below $150,000 per quality-adjusted life-year (QALY). [16] Arkansas Medicaid's acceptance of inclisiran under limited PA reflects that assessment.

Statin-intolerant patients with HeFH may also consider bempedoic acid (Nexletol) as an oral alternative, though its LDL-C reduction averages 18 to 21%, far below the 50% achieved with inclisiran in ORION-10. [3, 17]